Camel-IDS develops and commercializes radionuclide-based therapies for the treatment of breast cancer. Read more

Camel-IDS develops and commercializes radionuclide-based therapies for the treatment of breast cancer. Read more

Ruth Devenyns's photo - CEO of Camel-IDS

CEO

Ruth Devenyns

CEO Approval Rating

70/100

Founded:

2014

Status:

PrivateIndependent Company

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

NeoTherma Oncology is perceived as one of Camel-IDS's biggest rivals. NeoTherma Oncology is headquartered in Wichita, Kansas, and was founded in 2013. Like Camel-IDS, NeoTherma Oncology also operates in the Biotechnology industry. NeoTherma Oncology generates NaN% the revenue of Camel-IDS.

Clarity Pharmaceuticals is one of Camel-IDS's top competitors. Clarity Pharmaceuticals is a Private company that was founded in 2010 in Sydney, New South Wales. Clarity Pharmaceuticals operates in the Pharmaceuticals industry. Compared to Camel-IDS, Clarity Pharmaceuticals has 8 fewer employees.

Endocyte has been one of Camel-IDS's top competitors. Endocyte was founded in 1995 in West Lafayette, Indiana. Like Camel-IDS, Endocyte also works within the Biotechnology industry. Endocyte generates $2M less revenue than Camel-IDS.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Exelixis a competitor of Camel-IDS?

Acquisitions

No recent acquisitions found related to Camel-IDS

Camel-IDS Funding History

$41.8M

Since Camel-IDS was founded in 2014, it has participated in 1 round of funding. In total Camel-IDS has raised $41.8M. Camel-IDS's funding round was on Nov 2018 for a total of $41.8M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series A
Nov 2018
$41.8M

Gimv

Since Camel-IDS was founded in 2014, it has participated in 1 round of funding. In total Camel-IDS has raised $41.8M. Camel-IDS's funding round was on Nov 2018 for a total of $41.8M

Investments

No recent investments found related to Camel-IDS

Camel-IDS News

Social Media

Headquarters

Burgemeester Etienne Demunterlaan 1

Brussels, Brussels-Capital Region1090

32-2-479-93-60

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Camel-IDS develops and commercializes radionuclide-based therapies for the treatment of breast cancer. Camel-IDS was founded in 2014. Camel-IDS's headquarters is located in Brussels, Brussels-Capital Region, BE 1090. It has raised 41.8M in 1 round. Th...

CEO

Camel-IDS's CEO, Ruth Devenyns, currently has an approval rating of 70%. Camel-IDS's primary competitors are NeoTherma Oncology, Clarity Pharmaceuticals & Endocyte.

Website

camel-ids.com

Frequently Asked Questions about Camel-IDS

  1. When was Camel-IDS founded?

    Camel-IDS was founded in 2014
  2. Who is Camel-IDS's CEO?

    Camel-IDS's CEO is Ruth Devenyns
  3. How much revenue does Camel-IDS generate?

    Camel-IDS generates $2.1M in revenue
  4. How much funding does Camel-IDS have?

    Camel-IDS has historically raised $41.8M in funding
  1. Where is Camel-IDS's headquarters?

    Camel-IDS's headquarters is in Brussels Brussels-Capital Region, BE
  2. How many employees does Camel-IDS have?

    Camel-IDS has 28 employees
  3. What sector does Camel-IDS operate in?

    Camel-IDS is in Biotechnology
  4. Who are Camel-IDS's competitors?

    Camel-IDS's top competitors are NeoTherma Oncology, Clarity Pharmaceuticals, Endocyte